Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Lung Neoplasms 147Melanoma 92Squamous Cell Carcinoma of Head and Neck 70Carcinoma, Renal Cell 63Neoplasms 61Colorectal Neoplasms 61Triple Negative Breast Neoplasms 48Neoplasm Metastasis 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Ovarian Neoplasms 42Stomach Neoplasms 39Small Cell Lung Carcinoma 39Pancreatic Neoplasms 39Carcinoma, Transitional Cell 38Breast Neoplasms 38Head and Neck Neoplasms 34Uterine Cervical Neoplasms 30Endometrial Neoplasms 30Urinary Bladder Neoplasms 26Esophageal Neoplasms 24Carcinoma, Hepatocellular 24Mesothelioma 21Mesothelioma, Malignant 18Kidney Neoplasms 15Prostatic Neoplasms 14Adenocarcinoma of Lung 14Carcinoma 13Colonic Neoplasms 12Cholangiocarcinoma 12

Interventions

Carboplatin 2sintilimab 1pembrolizumab 1HLX07 1Gemcitabine 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous NSCLC × pembrolizumab × Thoracic × Clear all
NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Henlius Biotech

Phase 2/3 Not yet recruiting
720 enrolled
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡